News Release: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19 Commentary: New data, analyses take some of the shine off Merck’s Covid pill – STAT Related: 8 lingering questions about the new Covid pills from Merck and Pfizer. […]

The post [Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%. appeared first on Links Medicus.